Welireg (belzutifan) — United Healthcare
Advanced renal cell carcinoma (RCC)
Preferred products
- Keytruda (pembrolizumab)
- Opdivo (nivolumab)
- Cabometyx (cabozantinib)
- Inlyta (axitinib)
- Lenvima (lenvatinib)
Initial criteria
- Diagnosis of advanced renal cell carcinoma (RCC)
- Disease has progressed after treatment with both of the following: programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) checkpoint inhibitor [e.g., Keytruda (pembrolizumab), Opdivo (nivolumab)] AND vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) [e.g., Cabometyx (cabozantinib), Inlyta (axitinib), Lenvima (lenvatinib)]
Reauthorization criteria
- Patient does not show evidence of disease progression while on Welireg
Approval duration
12 months